[go: up one dir, main page]

AR133028A1 - Composición farmacéutica que comprende un degradador de todas las kras - Google Patents

Composición farmacéutica que comprende un degradador de todas las kras

Info

Publication number
AR133028A1
AR133028A1 ARP240101589A ARP240101589A AR133028A1 AR 133028 A1 AR133028 A1 AR 133028A1 AR P240101589 A ARP240101589 A AR P240101589A AR P240101589 A ARP240101589 A AR P240101589A AR 133028 A1 AR133028 A1 AR 133028A1
Authority
AR
Argentina
Prior art keywords
degrader
kras
pharmaceutical composition
composition including
colorectal
Prior art date
Application number
ARP240101589A
Other languages
English (en)
Inventor
Yoshihiro Nishizono
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of AR133028A1 publication Critical patent/AR133028A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporciona en la presente un compuesto de acuerdo con la fórmula (1), en donde R¹, R², R³, R⁴, A, X¹, Y, L, Z, R⁵, R⁶ᵃ, R⁶ᵇ, W y R⁷ son como se definen en la presente, para su uso en el tratamiento del cáncer colorrectal y/o de pulmón.
ARP240101589A 2023-06-22 2024-06-19 Composición farmacéutica que comprende un degradador de todas las kras AR133028A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP23180997 2023-06-22

Publications (1)

Publication Number Publication Date
AR133028A1 true AR133028A1 (es) 2025-08-20

Family

ID=86942863

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240101589A AR133028A1 (es) 2023-06-22 2024-06-19 Composición farmacéutica que comprende un degradador de todas las kras

Country Status (3)

Country Link
AR (1) AR133028A1 (es)
TW (1) TW202502762A (es)
WO (1) WO2024261256A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025168124A1 (zh) * 2024-02-08 2025-08-14 杭州多域生物技术有限公司 喹唑啉类化合物、其药物组合物及其应用
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2861066C (en) 2012-01-12 2024-01-02 Yale University Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an e3 ubiquitin ligase
KR20220101015A (ko) 2014-04-14 2022-07-18 아비나스 오퍼레이션스, 인코포레이티드 단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법
US10011600B2 (en) * 2014-09-25 2018-07-03 Araxes Pharma Llc Methods and compositions for inhibition of Ras
WO2016049565A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Compositions and methods for inhibition of ras
US10822312B2 (en) 2016-03-30 2020-11-03 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
KR20200010306A (ko) * 2017-05-25 2020-01-30 아락세스 파마 엘엘씨 Kras의 공유적 억제제
CN112218859B (zh) 2018-04-04 2024-10-29 阿尔维纳斯运营股份有限公司 蛋白水解调节剂及相关使用方法
WO2020018788A1 (en) 2018-07-20 2020-01-23 Dana-Farber Cancer Institute, Inc. Degraders that target proteins via keap1
PH12022550469A1 (en) 2019-08-29 2023-02-27 Array Biopharma Inc Kras g12d inhibitors
WO2021051034A1 (en) 2019-09-13 2021-03-18 Biotheryx, Inc. Ras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
WO2021106231A1 (en) 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
WO2022061348A1 (en) 2020-09-16 2022-03-24 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
WO2022087335A1 (en) 2020-10-23 2022-04-28 Biotheryx, Inc. Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
MX2023007084A (es) 2020-12-15 2023-08-30 Mirati Therapeutics Inc Inhibidores de pan-kras de azaquinazolina.
WO2022148421A1 (en) 2021-01-08 2022-07-14 Beigene, Ltd. Bridged compounds as kras g12d inhibitor and degrader and the use thereof
CR20230404A (es) 2021-02-15 2023-09-21 Astellas Pharma Inc Compuesto de quinazolina para inducir la degradación de la proteína kras mutante g12d

Also Published As

Publication number Publication date
WO2024261256A1 (en) 2024-12-26
TW202502762A (zh) 2025-01-16

Similar Documents

Publication Publication Date Title
AR133028A1 (es) Composición farmacéutica que comprende un degradador de todas las kras
AR126854A1 (es) Compuestos macrocíclicos para el tratamiento de cáncer
CL2023002090A1 (es) Inhibidores de kras tricíclicos fusionados
AR133027A1 (es) Composición farmacéutica que comprende un compuesto de quinazolina
CO2024001285A2 (es) Compuestos tricíclicos como inhibidores de kras
CO2021009882A2 (es) Inhibidores aza-heterobicíclicos de mat2a y métodos de uso en el tratamiento de cáncer
MX2022001908A (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina.
CO2021017981A2 (es) Inhibidores heterobicíclicos de mat2a y métodos de uso para el tratamiento del cáncer
MX2021014096A (es) Compuestos heterociclicos, metodos de preparacion y usos de estos.
CL2025000081A1 (es) Compuestos macrocíclicos inhibidores de kras y uso para tratar cáncer.
AR116283A1 (es) Inhibidores del sarcómero cardíaco
AR112797A1 (es) Inhibidores de kras g12c y métodos para utilizarlos
MX2023011715A (es) Compuestos de oxoisoindolina sustituidos con piridinilo.
BR112021017620A2 (pt) Compostos macrocíclicos
AR130984A1 (es) Compuestos novedosos
AR131006A1 (es) Compuestos novedosos
MX2025006661A (es) Inhibidores de polq
CL2023000061A1 (es) Macrociclos y su uso
UY39865A (es) Pirazin-2-carboxamidas sustituidas como inhibidores de hpk1 para el tratamiento del cáncer
CR20240533A (es) Macrociclos de indazol y su uso
AR120800A1 (es) Derivados de 6,7-dihidro-5h-pirrolo[1,2-c]imidazol como inhibidores de egfr
AR125479A1 (es) Inhibidores de il4i1 y métodos de uso
AR127496A1 (es) Compuestos de cd73
CL2025000396A1 (es) Combinaciones antineoplásicas que comprenden quimioterapia.
CO2024011221A2 (es) Compuestos y su uso en el tratamiento del cáncer